相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
PierFranco Conte et al.
CANCER (2020)
Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bNOMO breast cancer: a systematic review and meta-analysis
Hye Yoon Lee et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Aranzazu Fernandez-Martinez et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors
Martine J. Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy
Yanjie Shuai et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
Y. F. Yu et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Overview of Breast Cancer Therapy
Tracy-Ann Moo et al.
PET CLINICS (2018)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Neoadjuvant Therapy for HER2-positive Breast Cancer
Rachel Wuerstlein et al.
REVIEWS ON RECENT CLINICAL TRIALS (2017)
Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group
Samantha C. Sodergren et al.
TARGETED ONCOLOGY (2016)
The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer
Philip M. Spanheimer et al.
AMERICAN JOURNAL OF SURGERY (2013)
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
M. M. Kim et al.
ANNALS OF ONCOLOGY (2013)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Landmark Analysis at the 25-Year Landmark Point
Urania Dafni
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
The National Cancer Data Base: A powerful initiative to improve cancer care in the United States
Karl Y. Bilimoria et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer
Lisa C. Richardson et al.
BREAST JOURNAL (2007)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
分享论文
